Related references
Note: Only part of the references are listed.Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment
Sun Yoo et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Maria Gonzalez-Cao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection
Ilya Tsimafeyeu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain
Javier Crespo et al.
JOURNAL OF VIRAL HEPATITIS (2020)
An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders
Mar Riveiro-Barciela et al.
SCIENTIFIC REPORTS (2020)
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research
Douglas B Johnson et al.
LANCET ONCOLOGY (2020)
Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study
Edward Gane et al.
JOURNAL OF HEPATOLOGY (2019)
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
Xuanye Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
Neil J. Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series
Anita Kothapalli et al.
MELANOMA RESEARCH (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B
Anita Pandey et al.
CASE REPORTS IN ONCOLOGICAL MEDICINE (2018)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma
A. S. Koksal et al.
ANNALS OF ONCOLOGY (2017)
Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy
Adam C. Lake
AIDS (2017)
Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?
Barbara Vannata et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients With Resolved HBV Infection: A Prospective Study
Chiun Hsu et al.
HEPATOLOGY (2014)
Computerized Physician Order Entry-Based System to Prevent HBV Reactivation in Patients Treated With Biologic Agents: The PRESCRIB Project
Blanca Sampedro et al.
HEPATOLOGY (2014)
Hepatitis C Virus Screening in Patients With Cancer Receiving Chemotherapy
Jessica P. Hwang et al.
JOURNAL OF ONCOLOGY PRACTICE (2014)
Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center
Jessica P. Hwang et al.
BMC CANCER (2013)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2013)
Share Paper
